3
Announcements
Trials
Browse
Landscape
Status
Recruiting
5
Completed
4
Active not recruiting
3
Terminated
1
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma of Lung
1
Interventions
Suspensions
2
Powders
2
trametinib
1
talquetamab
1
taletrectinib
1
sotorasib
1
ruxolitinib
1
revumenib
1
omburtamab I-131
1
leronlimab
1
gallium maltolate
1
dabrafenib
1
ceritinib
1
capmatinib
1
asparaginase erwinia chrysanthemi recombinant
1
apalutamide
1
Standard of Care
1
Paclitaxel
1
Nivolumab
1
HMPL-013
1
Docetaxel
1
Asparaginase
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
No longer available
×
capmatinib
×
1 year
×
Clear all
NCT04741789
2026-03-16
Managed Access Programs for INC280, Capmatinib
Novartis
No longer available